<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vinod K Bhutani, MD, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Wong, BA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Almost all preterm infants less than 35 weeks gestational age (GA) have elevated total serum/plasma bilirubin (TB) levels. When adjusted for gestational and postnatal ages, preterm infants are inherently at greater risk than more mature infants (those born term or late preterm) for developing bilirubin-induced neurologic dysfunction (BIND), which, if not treated in a timely or appropriate manner, can result in chronic neurologic sequelae.</p><p>Hyperbilirubinemia in the preterm infant &lt;35 weeks GA will be reviewed here. The screening, evaluation, and management of hyperbilirubinemia in the late preterm and term infant are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications"</a> and  <a class="medical medical_review" href="/z/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a> and  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p class="headingAnchor" id="H801123749"><span class="h1">BILIRUBIN-INDUCED NEUROLOGIC DYSFUNCTION</span><span class="headingEndMark"> — </span>Clinical observational data in neonates have reported a spectrum of neurologic conditions among vulnerable neonates who have experienced an exposure to bilirubin of a lesser degree than generally associated with acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (CBE), respectively. This syndrome of bilirubin-induced neurologic dysfunction (BIND) is a major complication of an elevated total serum/plasma bilirubin (TB) level. Subtle clinical neuromotor manifestations include processing disorders with objective perturbations of visuomotor, auditory, speech, cognition, and language. Risk factors include prematurity, presence of hemolysis, perinatal-neonatal complications, altered bilirubin-albumin binding, and severity and duration of bilirubin exposure.</p><p>BIND occurs when unconjugated bilirubin, which is not bound to albumin (also referred to as "free" or "unbound bilirubin" [UB]), crosses the blood-brain barrier, enters the brain, and causes neurologic injury  (<a class="graphic graphic_figure graphicRef121543" href="/z/d/graphic/121543.html" rel="external">figure 1</a>). Neuronal damage affects several areas of the brain, including the pontine brainstem oculomotor nuclei globus pallidus, auditory pathways, hippocampus, diencephalon, subthalamic nuclei, cerebellum, and the vermis. The ensuing damage can result in acute bilirubin encephalopathy, and, if not treated, results in the posticteric neurologic manifestations that present as a chronic bilirubin encephalopathy (CBE), previously referred to as kernicterus [<a href="#rid1">1,2</a>]. These include disordered visual gaze (eg, limitations of upward gaze) [<a href="#rid3">3</a>], sensorineural hearing impairment [<a href="#rid4">4</a>], gait abnormalities (choreoathetoid cerebral palsy) [<a href="#rid5">5</a>], and speech and language disorders [<a href="#rid6">6</a>]. Subtle neuromotor signs are associated with a range of processing disorders due to visuo-oculomotor, auditory, speech, and expressive language disturbances. (See  <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Bilirubin-induced neurologic disorders (BIND)'</a>.)</p><p class="headingAnchor" id="H3616699369"><span class="h2">Increased vulnerability due to prematurity</span><span class="headingEndMark"> — </span>Preterm infants, compared with term infants, are more vulnerable to the syndrome of BIND and kernicterus at lower TB levels [<a href="#rid7">7</a>]. This increased susceptibility was first illustrated by case reports from the 1960s and 1970s in preterm infants with Rhesus isoimmune hemolytic disease [<a href="#rid8">8</a>]. Kernicterus was diagnosed in preterm infants at TB levels ranging from 10 to 18 mg/dL (171 to 308 micromol/L) compared with higher TB values associated with kernicterus in term infants (TB &gt;20 mg/dL [342 micromol/L]). </p><p>Limited data demonstrating the increased vulnerability include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis using information from several regional and national databases, preterm infants 32 to &lt;37 weeks GA were 20 percent more likely to develop CBE than those born at term [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A large retrospective analysis of extremely low birth weight (ELBW) infants (BW &lt;750 g) reported only a small association between modest levels of TB (5 to 12 mg/dL [85 to 204 micromol/L]) and a combined outcome of death and neurodevelopmental impairment (odds ratio [OR] 1.07, 95% CI 1.03-1.11), hearing impairment, and hearing impairment requiring hearing aids (OR 1.14, 95% CI 1.00-1.30) [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In small case reports of extremely preterm infants, CBE was associated with only moderately elevated TB [<a href="#rid7">7,11-13</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one case series, five preterm infants (25 to 29 weeks GA) with peak TB levels ranging from 8.7 to 11.9 mg/dL (149 to 203 micromol/L) had sensorineural hearing loss and magnetic resonance imaging (MRI) abnormalities in the globus pallidus [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a second report, all nine infants with auditory neuropathy spectrum disorder were born extremely preterm (median: 27.4 weeks GA) and all received phototherapy with a mean peak TB level of 11.9 mg/dL (203.6 micromol/L) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indirect evidence from a National Institute of Child Health and Human Development (NICHD) trial in very low birth weight (VLBW) infants (BW &lt;1000 g) showed more aggressive phototherapy (initiated at lower TB thresholds than those for conservative therapy) compared with conservative phototherapy was associated with a reduction of neurodevelopmental impairment (NDI) at 18 to 22 months corrected age [<a href="#rid14">14</a>]. However, a second published subanalysis reported aggressive phototherapy was associated with an increase in mortality for the most preterm infants (ie, ELBW infants [BW&lt;750 g]) who were mechanically ventilated, but the reduction of NDI persisted in survivors [<a href="#rid15">15</a>]. (See <a class="local">'Phototherapy and mortality'</a> below.)</p><p></p><p class="headingAnchor" id="H2667054009"><span class="h3">Hypoalbuminemia and bilirubin binding capacity (BBC)</span><span class="headingEndMark"> — </span>The increased vulnerability to BIND in preterm infants may be associated with hypoalbuminemia, which results in a decrease in BBC [<a href="#rid7">7,12,16-18</a>]. BBC defines the relationship between an infant's level of "free" or unbound bilirubin (UB) and his/her ability to "tolerate" increasing bilirubin loads. Hypoalbuminemia may be due to decreased synthesis, increased catabolism due to severe illness (eg, sepsis), and abnormal loss [<a href="#rid7">7</a>]. In addition, the decrease in BBC may be related to several factors that negatively affect bilirubin-albumin binding, including asphyxia, acidosis, sepsis, meningitis, and drug therapies that compete with bilirubin-binding sites (eg, sulfa drugs). However, one randomized controlled trial did not find that the use of B/A molar ratios improved neurodevelopmental outcome in infants ≤32 weeks GA [<a href="#rid19">19</a>]. (See <a class="local">'Other tests'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathogenesis of hyperbilirubinemia in the preterm infant is similar to that in the term infant (see  <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a>). Hyperbilirubinemia in preterm infants is more prevalent and protracted than that in term infants [<a href="#rid8">8</a>].</p><p>It is primarily caused by the following alterations in bilirubin metabolism compared with adults and more mature term infants  (<a class="graphic graphic_figure graphicRef121543" href="/z/d/graphic/121543.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Increased bilirubin production because of increased red blood cell (RBC) breakdown (turnover)</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased bilirubin clearance and conjugation (immature liver)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased enterohepatic circulation of bilirubin</p><p></p><p>In preterm infants, there also is often a delay in enteral feeds, which may limit intestinal flow and bacterial colonization, resulting in further enhancement of the enterohepatic circulation of bilirubin.</p><p class="headingAnchor" id="H11"><span class="h1">SCREENING FOR HYPERBILIRUBINEMIA</span></p><p class="headingAnchor" id="H203677498"><span class="h2">Approach to screening</span><span class="headingEndMark"> — </span>Screening for hyperbilirubinemia is based on the rationale that early identification and treatment of hyperbilirubinemia will reduce the risk of bilirubin-induced neurologic dysfunction (BIND), especially chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus). In our center, universal screening is performed with total serum/plasma bilirubin (TB) levels in all preterm infants beginning at 24 hours after birth or earlier if the neonate is at increased risk for developing hyperbilirubinemia. Subsequent TB levels are measured every 24 hours while the infant is in the neonatal intensive care unit (NICU) and the frequency is increased to every 12 hours if TB is approaching the threshold level for the initiation of phototherapy  (<a class="graphic graphic_figure graphicRef122659" href="/z/d/graphic/122659.html" rel="external">figure 2</a>) [<a href="#rid20">20-22</a>]. For infants &lt;35 weeks GA and not deemed ill, frequency of TB monitoring (by transcutaneous bilirubinometry [TcB] or by clinical lab assays) may be increased based on clinical judgment and risk factors. The clinician should consider using daily monitoring of jaundice progression, periodic TcB testing, and an infant's postnatal age in their assessment in order to minimize overtesting and overuse of phototherapy.</p><p class="headingAnchor" id="H1082032400"><span class="h2">Choice of screening test</span><span class="headingEndMark"> — </span>Our preferred screening test to identify preterm infants at-risk for hyperbilirubinemia is measuring TB. </p><p class="headingAnchor" id="H12"><span class="h3">Total serum/plasma bilirubin (TB)</span><span class="headingEndMark"> — </span>TB is the most frequent clinical laboratory test used to measure bilirubin and detect neonatal hyperbilirubinemia and is our preferred choice for screening in preterm infants. Although highly variable, it is the only available surrogate used to predict the risk of CBE (kernicterus). However, in extremely preterm infants, TB may not accurately reflect the concentration of free (unbound) bilirubin (UB) due to reduced and varied bilirubin binding capacity (BBC) for infants [<a href="#rid17">17</a>]. In this setting, UB testing (if available) or measuring the bilirubin/albumin (B/A) molar ratio may be appropriate. However, these tests are not universally available and may be found only in a research setting. (See <a class="local">'Hypoalbuminemia and bilirubin binding capacity (BBC)'</a> above and <a class="local">'Other tests'</a> below.)</p><p class="headingAnchor" id="H19983680"><span class="h3">Transcutaneous bilirubin (TcB)</span><span class="headingEndMark"> — </span>TcB devices are widely used to screen for hyperbilirubinemia in term and late preterm infants. However, due to limitations in their accuracy and precision, we do <strong>not</strong> recommend the routine use of TcB devices for assessing hyperbilirubinemia in preterm infants. Although, a 2013 systematic review suggested that TcB devices reported similar reliability in estimating TB in preterm infants less than 37 weeks GA compared with more mature infants [<a href="#rid23">23</a>], subsequent data showed that the correlation between TcB and TB decreases with decreasing gestational age [<a href="#rid24">24,25</a>]. For extremely preterm infants (&lt;30 weeks GA), the correlation of measurements between TcB and TB also varies depending on the body site used due to differences in tissue bilirubin binding [<a href="#rid26">26</a>]. </p><p>The concern of poorer reliability of TcB with decreasing GA is further heightened because intervention thresholds become narrower with increasing immaturity. As a result, TcB screening is not widely used [<a href="#rid27">27</a>]. Thus, we do <strong>not</strong> recommend the routine use of TcB devices in extremely preterm infants (gestational age &lt;28 weeks) until there are improved devices with better accuracy and precision, and a clinically validated standardized protocol for its use in preterm infants (GA &lt;35 weeks).</p><p class="headingAnchor" id="H1136982574"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>Other laboratory tests that are helpful in assessing the risk of hyperbilirubinemia but that are not routinely available include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free or unbound bilirubin (UB)</strong> – UB, especially in extremely preterm infants, may be a more appropriate predictor of BIND [<a href="#rid17">17,28-31</a>]. However, laboratory testing of UB is not universally available and is primarily used in a research setting. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilirubin/albumin (B/A) molar ratio</strong> – Preterm infants are likely to have low serum albumin levels, and it has been suggested that the B/A molar ratio would be a good measure of the risk of bilirubin toxicity based upon birth weight [<a href="#rid32">32,33</a>]. However, its usefulness has been limited in preterm infants, as other factors (eg, acidosis, use of multiple drugs, elevated free fatty acids, and presence of photoisomers) may interfere with B/A binding or binding of bilirubin to sites other than albumin [<a href="#rid30">30,34</a>]. As a result, we do not routinely check B/A in preterm infants.</p><p></p><p class="headingAnchor" id="H702522015"><span class="h1">CLINICAL PRESENTATIONS</span></p><p class="headingAnchor" id="H205760934"><span class="h2">Jaundice</span><span class="headingEndMark"> — </span>Jaundice is the yellow color produced by the deposition of bilirubin in the skin, subcutaneous tissues, and/or conjunctiva (as visualized on the sclerae). Although an important and time-honored clinical sign, the presence or absence of visible jaundice is not a reliable method to assess total serum/plasma bilirubin (TB) levels (or severity of hyperbilirubinemia). In particular, visual assessment for jaundice cannot be relied upon to identify elevated TB in extremely preterm infants (GA &lt;28 weeks), especially those with dark skin pigmentation, in whom phototherapy is used at much lower TB levels, or infants with rapidly rising TB levels. (See  <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Jaundice'</a>.)</p><p class="headingAnchor" id="H2641835279"><span class="h2">Neurologic findings</span><span class="headingEndMark"> — </span>Bilirubin-induced neurologic dysfunction (BIND) can present either acutely as acute bilirubin encephalopathy (ABE) or chronically as chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus). </p><p class="headingAnchor" id="H370812170"><span class="h3">Acute bilirubin encephalopathy (ABE)</span><span class="headingEndMark"> — </span>In preterm infants, the acute signs (eg, hypertonia, irritability, posturing, arching, and seizures) commonly seen in more mature neonates are not typically observed [<a href="#rid35">35,36</a>]. Preterm infants may only manifest minimal findings of recurrent apnea, periodic breathing, or episodes of oxygen desaturation, which may be masked in mechanically ventilated infants [<a href="#rid7">7</a>]. In one observational study from 1955 of preterm infants with gestational age (GA) &gt;30 weeks, signs and symptoms of ABE observed in the first 24 to 48 hours of birth included head retraction, expressionless facies (usually with oculogyric movements), changes in muscle tone, episodes of cyanosis, and lack of sucking [<a href="#rid37">37</a>].</p><p>In preterm infants, there is a disproportionately increased risk for sensorineural hearing loss (SNHL) [<a href="#rid38">38</a>]. As a result, automated auditory brainstem-evoked response (AABR) measurements is used to detect acute reversible bilirubin-induced auditory dysfunction, as well as irreversible SNHL [<a href="#rid32">32</a>]. In our center, an abnormal AABR is often used as another indicator for potential exchange transfusion. We perform AABR in all preterm infants (&lt;36 weeks’ GA) with elevated TB requiring intervention or who were admitted to the neonatal intensive care unit as they are at risk for SNHL, which cannot be detected by otoacoustic emissions. (See  <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Acute bilirubin encephalopathy (ABE)'</a> and  <a class="medical medical_review" href="/z/d/html/4985.html" rel="external">"Screening the newborn for hearing loss", section on 'Automated auditory brainstem response'</a>.)</p><p class="headingAnchor" id="H3989573628"><span class="h3">Chronic bilirubin encephalopathy (CBE) or kernicterus</span><span class="headingEndMark"> — </span>Chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus), is the chronic and irreversible form of BIND with permanent neurologic sequelae. The clinical features of CBE in preterm infants are similar to those observed in term infants, as the globus pallidus remains the primary target of brain injury. In addition to the following characteristic findings of CBE, these patients also display a range of processing disorders with disturbances of visuomotor, auditory, speech, cognition, and language [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Auditory neuropathy manifested as SNHL (abnormal AABR with normal otoacoustic emissions) – Observational studies suggest that isolated sensorineural hearing abnormalities may be the predominant or the sole manifestation of BIND. (See  <a class="medical medical_review" href="/z/d/html/6308.html" rel="external">"Hearing loss in children: Etiology", section on 'Hyperbilirubinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral palsy (CP) characterized by choreoathetosis. (See  <a class="medical medical_review" href="/z/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upward gaze abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enamel dysplasia of deciduous teeth.</p><p></p><p class="headingAnchor" id="H3566973034"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>In infants with BIND, abnormalities on magnetic resonance imaging (MRI) include increased signaling localized to the dentato-thalamo-cortical pathway [<a href="#rid39">39</a>]. In a small series, changes were seen in the globus pallidus with shifts from T1 increased signaling during the acute phase to permanent T2 hypersignaling and normal T1 signaling at 12 or 22 months corrected age [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1986889913"><span class="h1">MANAGEMENT APPROACH</span></p><p class="headingAnchor" id="H304519868"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Therapeutic interventions (ie, phototherapy and exchange transfusion) reduce total serum/plasma bilirubin (TB) levels in the blood and potentially prevent bilirubin-induced neurologic dysfunction (BIND). In term and late preterm infants (gestational age [GA] ≥35 weeks), hour-specific TB nomograms are used to guide decisions regarding initiating phototherapy and performing exchange transfusion [<a href="#rid40">40</a>] (see  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Thresholds for treatment'</a>). </p><p>In preterm infants &lt;35 weeks GA, similar guidelines are not available, despite observational evidence that suggests these preterm infants are more susceptible to BIND at lower TB levels than more mature infants. Nevertheless, based on consensus expert opinion and available data from studies from the National Institute of Child Health and Human Development (NICHD), we initiate therapy, primarily phototherapy, in infants &lt;35 weeks GA and who are &lt;7 days of age using a stratified approach based upon GA and TB [<a href="#rid10">10,14,20,21</a>]. The TB targets are in line with the more aggressive therapy used in the 2008 study based on data suggesting improved neurodevelopmental outcome [<a href="#rid10">10,14</a>].</p><p>The lack of an evidence-based consensus on the management of hyperbilirubinemia in the preterm infant is due to variabilities in the clinical manifestations and spectrum of BIND, absence of reliable and predictive measures of bilirubin neurotoxicity, and uncertainties of the relative risks and benefits of interventions to reduce TB levels (ie, phototherapy and exchange transfusions). A variety of approaches, including aggressive (early phototherapy at a low TB threshold level) and conservative treatment, have been proposed and generally are based upon using threshold TB levels stratified by birth weight (BW) [<a href="#rid41">41-45</a>]. (See <a class="local">'Benefit and risk'</a> below.)</p><p class="headingAnchor" id="H3020577285"><span class="h2">Initiation of phototherapy</span><span class="headingEndMark"> — </span>We initiate phototherapy for preterm infants based on GA and TB as follows  (<a class="graphic graphic_figure graphicRef122659" href="/z/d/graphic/122659.html" rel="external">figure 2</a>) [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>GA &lt;28 weeks – TB &gt;5 mg/dL (86 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 28 to 29 weeks – TB 6 to 8 mg/dL (103 to 137 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 30 to 31 weeks – TB 8 to 10 mg/dL (137 to 171 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 32 to 33 weeks – TB 10 to 12 mg/dL (171 to 205 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 34 to &lt;35 weeks – TB 12 to 14 mg/dL (205 to 239 micromol/L)</p><p></p><p>We suggest using devices with blue light-emitting diodes (LEDs) since they appear to achieve greater reduction in TB compared with other light sources [<a href="#rid46">46</a>]. Phototherapy is initially applied to the ventral body area with uniform exposure  (<a class="graphic graphic_picture graphicRef116147" href="/z/d/graphic/116147.html" rel="external">picture 1</a>) at an irradiance range of 15 to 30 microW/cm<sup>2</sup> per nm, depending on GA.</p><p>For rising TB levels, the intensity of phototherapy is increased in incremental steps based on GA as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;26 to 28 weeks GA:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Start with 25 to 30 microW/cm<sup>2</sup>/nm to one (dorsal/ventral) body surface.</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 25 to 30 microW/cm<sup>2</sup>/nm to both ventral and dorsal body surfaces.</p><p class="bulletIndent2"><span class="glyph">•</span>Pre-exchange – 30 microW/cm<sup>2</sup>/nm to both ventral and dorsal body surfaces. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>24 to &lt;26 weeks GA:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Start with 15 to 25 microW/cm<sup>2</sup>/nm to one (dorsal/ventral) body surface.</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 15 to 25 microW/cm<sup>2</sup>/nm to both ventral and dorsal body surfaces.</p><p class="bulletIndent2"><span class="glyph">•</span>Pre-exchange – 25 microW/cm<sup>2</sup>/nm to both ventral and dorsal body surfaces.</p><p></p><p>The use of phototherapy blanket allows exposure to both dorsal and ventral body surfaces. Infants who require this degree of intensive phototherapy often have a hemolytic disease and/or exposure to agents that may cause hemolysis. In these infants, other approaches, including exchange transfusion, may need to be considered. Because of concerns about the safety of phototherapy in extremely preterm infants, ongoing research is being conducted on alternative methods of providing phototherapy, including the use of lower irradiance levels and cycled phototherapy [<a href="#rid47">47,48</a>]. (See <a class="local">'Cycled versus continuous phototherapy'</a> below.)</p><p>Use of phototherapy in preterm neonates is discussed in greater detail below (see <a class="local">'Phototherapy'</a> below). Additional discussion of phototherapy more broadly is provided separately. (See  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Initial intervention (phototherapy)'</a>.) </p><p class="headingAnchor" id="H2123726181"><span class="h2">Indications for exchange transfusion</span><span class="headingEndMark"> — </span>Data supporting the indications for exchange transfusion are even more scant than that for phototherapy in preterm infants &lt;35 weeks GA. As a result, there is a wide practice variation, and the decision to perform an exchange transfusion in a preterm infant is based upon the clinical judgment of the attending neonatologist. Assessment of the risk/benefit ratio of an exchange transfusion needs to include the safety, efficiency, and known complications of an exchange transfusion. We recommend performing an exchange transfusion in any infant with neurologic signs consistent with BIND, and suggest exchange transfusion for preterm infants with a TB target level that fails to respond to phototherapy. </p><p>An operational guideline based on the preterm infant's BW was developed using data from the 1974 NICHD phototherapy trial [<a href="#rid41">41,42</a>]. We use this stratified approach using GA to consider exchange transfusions in preterm infants without neurologic findings based on the NICHD data and published expert opinions, including the authors' [<a href="#rid21">21</a>]. For infants whose TB levels are approaching the threshold TB level for exchange transfusion, intensive phototherapy is administered. TB is measured every 4 to 8 hours to determine whether there is an adequate response, thus avoiding exchange transfusion. </p><p>Exchange transfusion is indicated based on GA and TB as follows  (<a class="graphic graphic_figure graphicRef122659" href="/z/d/graphic/122659.html" rel="external">figure 2</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>GA &lt;28 weeks – TB 11 to 14 mg/dL (188 to 239 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 28 to 29 weeks – TB 12 to 14 mg/dL (205 to 239 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 30 to 31 weeks – TB 13 to 16 mg/dL (222 to 274 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA 32 to 33 weeks – TB 15 to 18 mg/dL (257 to 308 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>GA &gt;34 weeks – TB 17 to 19 mg/dL (291 to 325 micromol/L)</p><p></p><p>During the exchange transfusion, phototherapy is continued, although a single device may only be used. After completion of the exchange transfusion, phototherapy is restarted at the same dosing prior to procedure. TB is remeasured hours after the exchange transfusion is completed. </p><p class="headingAnchor" id="H4256452127"><span class="h2">Other approaches</span><span class="headingEndMark"> — </span>Examples of guidelines from other countries for the management of hyperbilirubinemia include those developed in the United Kingdom and Norway:</p><p class="bulletIndent1"><span class="glyph">●</span>The United Kingdom guideline to initiate phototherapy and exchange transfusion is based on consensus opinion and reported care practice in neonatal units (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fcg98&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dMlNUvaIqJa1yaq6fzufFBA&amp;TOPIC_ID=5037" target="_blank">National Institute for Health and Care Excellence [NICE] guideline for neonatal jaundice</a>). The threshold to initiate treatment for preterm infants greater than 72 hours of age is determined using the following formula that incorporates GA (weeks).</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Total bilirubin in micromol/L = (GA × 10) – 100</p></div></div><p></p><p class="bulletIndent1"><span class="glyph">●</span>The guideline to initiate phototherapy from Norway is based on the BW and postnatal age of the preterm infant [<a href="#rid49">49</a>]. In general, for infants &gt;4 days of age, the following threshold levels of TB are used based on BW:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BW &gt;2500 g, but GA between 34 and 37 weeks – 17.5 mg/dL (300 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>BW between 1500 and 2500 g – 14.6 mg/dL (250 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>BW between 1000 and 1499 g – 11.7 mg/dL (200 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>BW between &lt;1000 g – 8.8 mg/dL (150 micromol/L)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">INTERVENTIONS</span></p><p class="headingAnchor" id="H15"><span class="h2">Phototherapy</span></p><p class="headingAnchor" id="H2426834044"><span class="h3">Benefit and risk</span><span class="headingEndMark"> — </span>Phototherapy is the most commonly used intervention to treat and prevent severe hyperbilirubinemia, including in preterm infants, as it has been shown to reduce total serum/plasma bilirubin (TB) [<a href="#rid46">46</a>]. Preterm infants born &lt;35 weeks gestational age (GA) are at greater risk to develop bilirubin-induced neurologic dysfunction (BIND) than the more mature infants [<a href="#rid8">8</a>]. However, the prevalence of chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus) has decreased to the point where CBE is rare. The use of phototherapy as outlined above has dramatically reduced the need for exchange transfusions, particularly in infants of birth weight &lt;1500 g [<a href="#rid50">50,51</a>]. However, there are concerns of potential risks associated with phototherapy, including increased mortality in the most immature infants (birth weight [BW] &lt;750 g). Nevertheless, based on the available evidence, we continue to use phototherapy using threshold bilirubin for different GAs to prevent and/or reduce the severity of BIND. (See <a class="local">'Initiation of phototherapy'</a> above.)</p><p class="headingAnchor" id="H2277056350"><span class="h4">Phototherapy and mortality</span><span class="headingEndMark"> — </span>Concerns have been raised that phototherapy may be harmful to extremely preterm (EPT) infants (GA &lt;28 weeks). The proposed mechanisms are that phototherapy may cause direct photo-oxidative injury to cell membranes or it may indirectly cause injury by reducing bilirubin levels, which may play a protective antioxidant role. In either case, the most immature infants would be most susceptible as there is greater transmission of potentially toxic light through their thin, gelatinous skin, and they are at the greatest risk for oxidant injury because of reduced natural antioxidants.</p><p>However, data are conflicting regarding the association of phototherapy and mortality in EPT infants: </p><p class="bulletIndent1"><span class="glyph">●</span>A NICHD trial of 1974 extremely low birth weight (ELBW) (BW &lt;1000 g) randomly assigned and stratified based on BW (low BW: 501 to 750 g and high BW: 751 to 1000 g) aggressive (initiated at a lower TB threshold) or conservative phototherapy [<a href="#rid14">14</a>]. Mean peak TB levels were lower using aggressive phototherapy (7 versus 9.8 mg/dL [120 versus 168 micromol/L]), and there were no differences in the primary composite outcome of death or neurodevelopmental impairment (NDI) at 18 to 22 months corrected age between aggressive and conservative therapy (52 versus 55 percent, relative risk [RR] 0.94, 95% CI 0.87-1.02), or death (24 versus 23 percent. RR 1.05, 95% CI 0.90-1.22). </p><p></p><p class="bulletIndent1">However, a second published subanalysis reported that aggressive phototherapy compared with conservative phototherapy was associated with increased mortality for the most preterm infants (BW 501 to 750 g) who were mechanically ventilated and a reduction in NDI at 18 to 22 months corrected age [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a NICHD trial of 1802 patients (91.4 percent of the original cohort) of whom 1607 received phototherapy treatment (PTx) and 195 did not (NoPTx), reported phototherapy was not independently associated with the primary outcome at 18 to 22 months corrected age of death or NDI, death alone, or NDI [<a href="#rid52">52</a>]. In this cohort, the NoPTx group had a higher mean BW and GA, and rate of caesarean section, and was more likely to have mothers with a lower educational level. Subgroup analyses based on BWs reported a trend for higher mortality for infants with BWs between 501 and 750 for the NoPTX versus PTx group (47 versus 36 percent, odds ratio [OR] 0.58, 95% CI 0.32-1.04).</p><p></p><p class="headingAnchor" id="H89823926"><span class="h3">Technique and light sources</span><span class="headingEndMark"> — </span>We suggest blue light-emitting diodes (LEDs) as the light source for phototherapy as they appear to achieve greater reduction in TB levels compared with other light sources in preterm infants [<a href="#rid46">46</a>]. In a study from the National Institute of Child Health and Human Development (NICHD) comparing different phototherapy devices in EPT infants, the absolute decrease in TB levels during the first 24 hours of therapy was greatest for devices with blue LEDs (2.2 mg/dL) followed by halogen spotlights (1.7 mg/dL), fluorescent light banks (1.3 mg/dL), and blankets (0.8 mg/dL) [<a href="#rid46">46</a>]. </p><p>If fiberoptic blankets are used in ELBW infants, caution should be used to minimize risk of skin breakdown.</p><p>The procedure for administering phototherapy and selection of light sources are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Administration'</a>.).</p><p class="headingAnchor" id="H680551059"><span class="h3">Cycled versus continuous phototherapy</span><span class="headingEndMark"> — </span>Because of the concern that phototherapy may contribute to an increase in mortality risk for EPT infants, it has been proposed that cycled rather than continuous phototherapy would lessen phototherapy exposure, thereby reducing side effects associated with prolonged light exposure, and still adequately control and reduce TB levels. A multicenter trial of EPT infants reported that cycled (≥15 min/hour) versus continuous phototherapy reduced phototherapy exposure (34 versus 72 hours, adjusted difference -40 hours, 95% CI -45 to -32 hours) with only a slight increase in mean peak TB (7.1 versus 6.4 mg/dL [121 versus 109 micromol/L], adjusted difference 0.7 mg/dL, 95% CI 0.4 to 1.1 mg/dL [12 micromol/L, 95% CI 7 to 19]) [<a href="#rid53">53</a>]. In a subset of patients, there was no difference in predischarge brainstem auditory-evoked response (BAER) wave V latency between the two treatment regimens. Based on these results, future larger trials are being planned to determine whether cycled phototherapy would improve survival without further NDI in EPT infants. </p><p class="headingAnchor" id="H88254618"><span class="h3">Prophylactic phototherapy</span><span class="headingEndMark"> — </span>We suggest not using prophylactic phototherapy given the potential risks associated with phototherapy. Although there are some data to suggest prophylactic phototherapy would prevent hyperbilirubinemia [<a href="#rid54">54</a>], prophylactic use would needlessly expose some preterm infants to phototherapy who would otherwise never require phototherapy and potentially lead to increased costs and potential adverse outcomes for preterm infants.</p><p class="headingAnchor" id="H16"><span class="h2">Exchange transfusion</span><span class="headingEndMark"> — </span>Data to support the indications for exchange transfusion are even more scant than those for phototherapy in infants &lt;35 weeks GA. Information on the efficacy of exchange transfusion is extrapolated from observational data from term infants. Discussion on the benefit and risk of exchange transfusion and a description of the procedure are found separately. (See  <a class="medical medical_review" href="/z/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care", section on 'Exchange transfusion'</a>.)</p><p class="headingAnchor" id="H1087422428"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Infants exposed to elevated total serum/plasma bilirubin (TB) level (hyperbilirubinemia) are at-risk for bilirubin-induced neurologic dysfunction (BIND). Preterm infants, compared with term infants, appear to be more vulnerable to BIND at lower TB levels. In addition, hyperbilirubinemia in preterm infants is more prevalent and protracted than in term infants because of the immaturity of their red blood cells (RBCs), livers, and gastrointestinal tracts  (<a class="graphic graphic_figure graphicRef121543" href="/z/d/graphic/121543.html" rel="external">figure 1</a>). (See <a class="local">'Bilirubin-induced neurologic dysfunction'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Screening for hyperbilirubinemia is based on the rationale that early identification and treatment of hyperbilirubinemia will reduce the risk of BIND. In our center, we screen all preterm neonates admitted to the neonatal intensive care unit with a TB level in the first 24 hours after birth, with subsequent testing performed every 24 hours. The frequency of testing increases as TB level approach thresholds for interventions. (See <a class="local">'Screening for hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinical findings of hyperbilirubinemia are due to bilirubin deposition in the skin (jaundice) and the brain. (See <a class="local">'Clinical presentations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Jaundice is the yellowish discoloration of the skin, subcutaneous tissue, and/or conjunctiva (as visualized on the sclerae) caused by bilirubin deposition. (See <a class="local">'Jaundice'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In preterm infants &lt;35 weeks gestational age (GA), the acute neurologic signs (eg, hypertonia, irritability, posturing, arching, and seizures) commonly seen in more mature neonates are not typically observed. Preterm infants may only manifest minimal findings of recurrent apnea, periodic breathing, or episodes of oxygen desaturation, which may be masked in mechanically ventilated infants. Automated auditory brainstem-evoked response (AABR) may detect acute reversible bilirubin-induced auditory dysfunction. (See <a class="local">'Acute bilirubin encephalopathy (ABE)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus), is the chronic form of BIND associated with permanent neurologic sequelae. The clinical manifestations of CBE in preterm infants are similar to those observed in term infants and include choreoathetoid cerebral palsy, sensorineural hearing loss, upward gaze abnormalities, and enamel dysplasia of deciduous teeth. (See <a class="local">'Chronic bilirubin encephalopathy (CBE) or kernicterus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management approach</strong> – A threshold TB level that is predictive of neurologic sequelae in preterm infants has yet to be identified. As a result, consensus is lacking on the optimal management hyperbilirubinemia in infants &lt;35 weeks GA. Our suggested approach is as follows (see <a class="local">'Management approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phototherapy</strong> – For preterm infants &lt;35 weeks GA and &lt;7 days old, we suggest starting phototherapy based upon the following GA and TB thresholds  (<a class="graphic graphic_figure graphicRef122659" href="/z/d/graphic/122659.html" rel="external">figure 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)(see <a class="local">'Initiation of phototherapy'</a> above and <a class="local">'Benefit and risk'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>GA &lt;28 weeks – TB &gt;5 mg/dL (86 micromol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>GA 28 to 29 weeks – TB 6 to 8 mg/dL (103 to 137 micromol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>GA 30 to 31 weeks – TB 8 to 10 mg/dL (137 to 171 micromol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>GA 32 to 33 weeks – TB 10 to 12 mg/dL (171 to 205 micromol/L)</p><p class="bulletIndent3"><span class="glyph">-</span>GA 34 to &lt;35 weeks – TB 12 to 14 mg/dL (205 to 239 micromol/L)</p><p></p><p class="bulletIndent2">Other centers base decisions on TB levels stratified by birthweight. We suggest blue light-emitting diodes (LEDs) rather than other light sources for phototherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) since they appear to achieve greater reduction in TB levels. Phototherapy is initially applied to the ventral body area with uniform exposure  (<a class="graphic graphic_picture graphicRef116147" href="/z/d/graphic/116147.html" rel="external">picture 1</a>) at an irradiance of 15 to 30 microW/cm<sup>2</sup> per nm depending on GA. (See <a class="local">'Technique and light sources'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exchange transfusion</strong> – For preterm infants &lt;35 weeks GA with hyperbilirubinemia that does not respond adequately to intensive phototherapy and that exceeds the TB threshold level based on GA  (<a class="graphic graphic_figure graphicRef122659" href="/z/d/graphic/122659.html" rel="external">figure 2</a>), we suggest performing exchange transfusion (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Indications for exchange transfusion'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bhutani VK, Wong R. Bilirubin-induced neurologic dysfunction (BIND). Semin Fetal Neonatal Med 2015; 20:1.</a></li><li><a class="nounderline abstract_t">Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol 2011; 35:101.</a></li><li><a class="nounderline abstract_t">Good WV, Hou C. Visuocortical bilirubin-induced neurological dysfunction. Semin Fetal Neonatal Med 2015; 20:37.</a></li><li><a class="nounderline abstract_t">Olds C, Oghalai JS. Audiologic impairment associated with bilirubin-induced neurologic damage. Semin Fetal Neonatal Med 2015; 20:42.</a></li><li><a class="nounderline abstract_t">Rose J, Vassar R. Movement disorders due to bilirubin toxicity. Semin Fetal Neonatal Med 2015; 20:20.</a></li><li><a class="nounderline abstract_t">Wusthoff CJ, Loe IM. Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. Semin Fetal Neonatal Med 2015; 20:52.</a></li><li><a class="nounderline abstract_t">Watchko JF. Bilirubin-Induced Neurotoxicity in the Preterm Neonate. Clin Perinatol 2016; 43:297.</a></li><li><a class="nounderline abstract_t">Watchko JF, Maisels MJ. Jaundice in low birthweight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed 2003; 88:F455.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013; 74 Suppl 1:86.</a></li><li><a class="nounderline abstract_t">Oh W, Tyson JE, Fanaroff AA, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003; 112:773.</a></li><li><a class="nounderline abstract_t">Moll M, Goelz R, Naegele T, et al. Are recommended phototherapy thresholds safe enough for extremely low birth weight (ELBW) infants? A report on 2 ELBW infants with kernicterus despite only moderate hyperbilirubinemia. Neonatology 2011; 99:90.</a></li><li><a class="nounderline abstract_t">Govaert P, Lequin M, Swarte R, et al. Changes in globus pallidus with (pre)term kernicterus. Pediatrics 2003; 112:1256.</a></li><li><a class="nounderline abstract_t">Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for auditory neuropathy spectrum disorder in NICU infants compared to normal-hearing NICU controls. Laryngoscope 2011; 121:852.</a></li><li><a class="nounderline abstract_t">Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008; 359:1885.</a></li><li><a class="nounderline abstract_t">Tyson JE, Pedroza C, Langer J, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? J Perinatol 2012; 32:677.</a></li><li><a class="nounderline abstract_t">Lamola AA, Bhutani VK, Du L, et al. Neonatal bilirubin binding capacity discerns risk of neurological dysfunction. Pediatr Res 2015; 77:334.</a></li><li><a class="nounderline abstract_t">Amin SB, Wang H. Bilirubin Albumin Binding and Unbound Unconjugated Hyperbilirubinemia in Premature Infants. J Pediatr 2018; 192:47.</a></li><li><a class="nounderline abstract_t">Kim MH, Yoon JJ, Sher J, Brown AK. Lack of predictive indices in kernicterus: a comparison of clinical and pathologic factors in infants with or without kernicterus. Pediatrics 1980; 66:852.</a></li><li><a class="nounderline abstract_t">Hulzebos CV, Dijk PH, van Imhoff DE, et al. The bilirubin albumin ratio in the management of hyperbilirubinemia in preterm infants to improve neurodevelopmental outcome: a randomized controlled trial--BARTrial. PLoS One 2014; 9:e99466.</a></li><li><a class="nounderline abstract_t">Palma JP, Arain YH. Development of a Web-Based Decision Support Tool to Operationalize and Optimize Management of Hyperbilirubinemia in Preterm Infants. Clin Perinatol 2016; 43:375.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32:660.</a></li><li><a class="nounderline abstract_t">Wallenstein MB, Bhutani VK. Jaundice and kernicterus in the moderately preterm infant. Clin Perinatol 2013; 40:679.</a></li><li><a class="nounderline abstract_t">Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of transcutaneous bilirubin devices in preterm infants: a systematic review. Pediatrics 2013; 132:871.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Coffey MP, Kring E. Transcutaneous bilirubin levels in newborns &lt;35 weeks' gestation. J Perinatol 2015; 35:739.</a></li><li><a class="nounderline abstract_t">Arman D, Topcuoğlu S, Gürsoy T, et al. The accuracy of transcutaneous bilirubinometry in preterm infants. J Perinatol 2020; 40:212.</a></li><li><a class="nounderline abstract_t">Kurokawa D, Nakamura H, Yokota T, et al. Screening for Hyperbilirubinemia in Japanese Very Low Birthweight Infants Using Transcutaneous Bilirubinometry. J Pediatr 2016; 168:77.</a></li><li><a class="nounderline abstract_t">Bhatt DR, Kristensen-Cabrera AI, Lee HC, et al. Transcutaneous bilirubinometer use and practices surrounding jaundice in 150 California newborn intensive care units. J Perinatol 2018; 38:1532.</a></li><li><a class="nounderline abstract_t">Wennberg RP, Ahlfors CE, Bhutani VK, et al. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006; 117:474.</a></li><li><a class="nounderline abstract_t">Nakamura H, Yonetani M, Uetani Y, et al. Determination of serum unbound bilirubin for prediction of kernicterus in low birthweight infants. Acta Paediatr Jpn 1992; 34:642.</a></li><li><a class="nounderline abstract_t">Hulzebos CV, van Imhoff DE, Bos AF, et al. Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants. Arch Dis Child Fetal Neonatal Ed 2008; 93:F384.</a></li><li><a class="nounderline abstract_t">Oh W, Stevenson DK, Tyson JE, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010; 99:673.</a></li><li><a class="nounderline abstract_t">Ahlfors CE, Amin SB, Parker AE. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. J Perinatol 2009; 29:305.</a></li><li><a class="nounderline abstract_t">Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488.</a></li><li><a class="nounderline abstract_t">Hulzebos CV, van Dommelen P, Verkerk PH, et al. Evaluation of treatment thresholds for unconjugated hyperbilirubinemia in preterm infants: effects on serum bilirubin and on hearing loss? PLoS One 2013; 8:e62858.</a></li><li><a class="nounderline abstract_t">Okumura A, Kidokoro H, Shoji H, et al. Kernicterus in preterm infants. Pediatrics 2009; 123:e1052.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Johnson LH, Shapiro SM. Kernicterus in sick and preterm infants (1999-2002): a need for an effective preventive approach. Semin Perinatol 2004; 28:319.</a></li><li><a class="nounderline abstract_t">CROSSE VM, MEYER TC, GERRARD JW. Kernicterus and prematurity. Arch Dis Child 1955; 30:501.</a></li><li><a class="nounderline abstract_t">Singh A, Francis HW, Smith PB, et al. Association between Hyperbilirubinemia and Hearing Screen Failure in the Neonatal Intensive Care Unit in Infants Born Preterm. J Pediatr 2021; 231:68.</a></li><li><a class="nounderline abstract_t">Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways. J Pediatr 2016; 174:260.</a></li><li><a class="nounderline abstract_t">Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Lee KS, Gartner LM. Management of unconjugated hyperbilirubinemia in the newborn. Semin Liver Dis 1983; 3:52.</a></li><li><a class="nounderline abstract_t">Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985; 75:393.</a></li><li class="breakAll">Maisels MJ. Neonatology: Pathophysiology and Management of the Newborn, 6th ed, Avery GB, Fletcher MA, Macdonald MG (Eds), Lippincott Williams &amp; Wilkins, 2005.</li><li class="breakAll">Ives NK. Neonatal jaundice. In: Textbook of Neonatology, 3rd ed, Rennie JM (Ed), Churchill Livingston, Edinburgh 2005. p.675.</li><li><a class="nounderline abstract_t">Maisels MJ, Watchko JF. Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003; 88:F459.</a></li><li><a class="nounderline abstract_t">Morris BH, Tyson JE, Stevenson DK, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. J Perinatol 2013; 33:126.</a></li><li class="breakAll">Arnold C, Tyson JE, Castillo Cuadrado ME, et al. Cycled phototherapy: A safer effective treatment for small premature infants with hyperbilirubinemia. E-PAS2015:1582.605. Presented at the 2015 Pediatric Academic Society Meeting. www.abstracts2view.com/pas/view.php?nu=PAS15L1_1582.605 (Accessed on August 26, 2015).</li><li><a class="nounderline abstract_t">Arnold C, Pedroza C, Tyson JE. Phototherapy in ELBW newborns: does it work? Is it safe? The evidence from randomized clinical trials. Semin Perinatol 2014; 38:452.</a></li><li><a class="nounderline abstract_t">Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011; 100:499.</a></li><li><a class="nounderline abstract_t">Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 2007; 120:27.</a></li><li><a class="nounderline abstract_t">Maisels MJ. Phototherapy--traditional and nontraditional. J Perinatol 2001; 21 Suppl 1:S93.</a></li><li><a class="nounderline abstract_t">Hintz SR, Stevenson DK, Yao Q, et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? Acta Paediatr 2011; 100:960.</a></li><li><a class="nounderline abstract_t">Arnold C, Tyson JE, Pedroza C, et al. Cycled Phototherapy Dose-Finding Study for Extremely Low-Birth-Weight Infants: A Randomized Clinical Trial. JAMA Pediatr 2020; 174:649.</a></li><li><a class="nounderline abstract_t">Okwundu CI, Okoromah CA, Shah PS. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev 2012; 1:CD007966.</a></li></ol></div><div id="topicVersionRevision">Topic 5037 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577656" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bilirubin-induced neurologic dysfunction (BIND).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641482" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The clinical syndrome of bilirubin-induced neurologic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577655" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Visuocortical bilirubin-induced neurological dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575899" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Audiologic impairment associated with bilirubin-induced neurologic damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524299" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Movement disorders due to bilirubin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25585889" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235209" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bilirubin-Induced Neurotoxicity in the Preterm Neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602689" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Jaundice in low birthweight infants: pathobiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366465" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523165" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639681" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Are recommended phototherapy thresholds safe enough for extremely low birth weight (ELBW) infants? A report on 2 ELBW infants with kernicterus despite only moderate hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654594" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Changes in globus pallidus with (pre)term kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21305553" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for auditory neuropathy spectrum disorder in NICU infants compared to normal-hearing NICU controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971491" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aggressive vs. conservative phototherapy for infants with extremely low birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22652561" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25420178" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neonatal bilirubin binding capacity discerns risk of neurological dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29132818" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bilirubin Albumin Binding and Unbound Unconjugated Hyperbilirubinemia in Premature Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192847" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lack of predictive indices in kernicterus: a comparison of clinical and pathologic factors in infants with or without kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24927259" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The bilirubin albumin ratio in the management of hyperbilirubinemia in preterm infants to improve neurodevelopmental outcome: a randomized controlled trial--BARTrial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235214" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development of a Web-Based Decision Support Tool to Operationalize and Optimize Management of Hyperbilirubinemia in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22678141" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182955" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Jaundice and kernicterus in the moderately preterm infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127472" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reliability of transcutaneous bilirubin devices in preterm infants: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26110497" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transcutaneous bilirubin levels in newborns&lt;35 weeks' gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31363143" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The accuracy of transcutaneous bilirubinometry in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410797" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Screening for Hyperbilirubinemia in Japanese Very Low Birthweight Infants Using Transcutaneous Bilirubinometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30120424" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Transcutaneous bilirubinometer use and practices surrounding jaundice in 150 California newborn intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452368" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1285512" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Determination of serum unbound bilirubin for prediction of kernicterus in low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450807" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105142" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242487" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8115210" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Criteria for exchange transfusion in jaundiced newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23667532" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evaluation of treatment thresholds for unconjugated hyperbilirubinemia in preterm infants: effects on serum bilirubin and on hearing loss?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433515" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kernicterus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686262" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Kernicterus in sick and preterm infants (1999-2002): a need for an effective preventive approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13275980" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Kernicterus and prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359471" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association between Hyperbilirubinemia and Hearing Screen Failure in the Neonatal Intensive Care Unit in Infants Born Preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113379" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6403991" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Management of unconjugated hyperbilirubinemia in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881731" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881731" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881731" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602690" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of jaundice in low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499082" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499082" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308614" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phototherapy in ELBW newborns: does it work? Is it safe? The evidence from randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114525" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : National guidelines for treatment of jaundice in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606558" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11803426" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phototherapy--traditional and nontraditional.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272067" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338720" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cycled Phototherapy Dose-Finding Study for Extremely Low-Birth-Weight Infants: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258977" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
